1. Home
  2. SPCE vs TLSI Comparison

SPCE vs TLSI Comparison

Compare SPCE & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virgin Galactic Holdings Inc.

SPCE

Virgin Galactic Holdings Inc.

N/A

Current Price

$2.98

Market Cap

331.6M

ML Signal

N/A

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

HOLD

Current Price

$4.92

Market Cap

270.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPCE
TLSI
Founded
2017
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Transportation Services
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
331.6M
270.2M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
SPCE
TLSI
Price
$2.98
$4.92
Analyst Decision
Hold
Strong Buy
Analyst Count
5
1
Target Price
$3.06
$7.00
AVG Volume (30 Days)
8.2M
183.0K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
60.84
N/A
EPS
N/A
N/A
Revenue
$1,544,000.00
$45,151,000.00
Revenue This Year
$2,270.73
$35.45
Revenue Next Year
$880.03
$37.58
P/E Ratio
N/A
N/A
Revenue Growth
N/A
53.41
52 Week Low
$2.13
$2.20
52 Week High
$8.90
$7.95

Technical Indicators

Market Signals
Indicator
SPCE
TLSI
Relative Strength Index (RSI) 47.29 47.88
Support Level $2.84 $4.21
Resistance Level $3.39 $5.58
Average True Range (ATR) 0.17 0.27
MACD -0.03 -0.09
Stochastic Oscillator 12.70 7.76

Price Performance

Historical Comparison
SPCE
TLSI

About SPCE Virgin Galactic Holdings Inc.

Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: